Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21130530 | 0.91 | CD274 (0.48) | CD274PDCD1 | |
| SCHEMBL21130428 | 0.90 | CD274 (0.48) | CD274PDCD1 | |
| SCHEMBL19897846 | 0.87 | CD274 (0.54) | CD274PDCD1 | |
| SCHEMBL21130422 | 0.86 | CD274 (0.47) | CD274PDCD1 | |
| SCHEMBL21130534 | 0.86 | CD274 (0.52) | CD274PDCD1 | |
| SCHEMBL20721107 | 0.86 | CD274 (0.65) | CD274PDCD1 | |
| SCHEMBL21130665 | 0.85 | CD274 (0.48) | CD274PDCD1 | |
| SCHEMBL21130661 | 0.85 | CD274 (0.49) | CD274PDCD1 | |
| SCHEMBL21130482 | 0.84 | CD274 (0.47) | CD274PDCD1 | |
| SCHEMBL21130531 | 0.84 | CD274 (0.47) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689640-B | Compounds useful as immunomodulators | 百时美施贵宝公司 | 2022-01-04 | — | — | CN | disclosed |
| EP-3481815-B1 | 1,3-DIHYDROXY-PHENYL DERIVATIVES USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10590105-B2 | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190185450-A1 | 1,3-DIHYDROXY-PHENYL DERIVATIVES USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185450-A1 | 1,3-DIHYDROXY-PHENYL DERIVATIVES USEFUL AS IMMUNOMODULATORS | CD74, CD2, HAVCR2 | CD274 30/4885PDCD1 46/4885 |
| US-10590105-B2 | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | CD74, CD2, HAVCR2 | CD274 30/4885PDCD1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.